Company intelligence / Profile preview
Enzyme by Design
Chicago, Illinois, United Statesenzymebydesign.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Preclinical
01
Overview
Enzyme by Design’s lead program, EbD-1117, is a humanized L-asparaginase engineered to eliminate glutaminase activity—reducing the toxic side effects seen in current asparaginases. In mouse models of T-cell and B-cell ALL, EbD-1117 demonstrated efficacy comparable to standard therapies but with significantly less weight loss and reduced liver toxicity. The company aims to enter clinical trials after completing IND-enabling studies.
- Therapeutic areas
- Oncology
- Modalities
- Recombinant proteinEnzyme therapyBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
None publicly disclosed as of June 2025. Participates in NIH I-CORP program for industry engagement.
Beyond the preview
Go deeper on Enzyme by Design.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enzyme by Design.